Drug Type Drug conjugates |
Synonyms CEACAM5 targets Fab+SQP22(Shasqi) |
Target |
Action antagonists, inhibitors |
Mechanism CEACAM5 antagonists(Carcinoembryonic antigen related cell adhesion molecule 5 antagonists), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC39H67N5O7 |
InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N |
CAS Registry474645-27-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 27 Apr 2025 |